Tadalafil - Druggability Technologies

Drug Profile

Tadalafil - Druggability Technologies

Alternative Names: DRGT 99

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Druggability Technologies
  • Class Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Erectile dysfunction

Most Recent Events

  • 15 May 2017 Phase-I clinical trials in Erectile dysfunction before May 2017 (Druggability Technologies pipeline, May 2017)
  • 12 Dec 2016 Chemical structure information added
  • 07 Dec 2016 Preclinical trials in Erectile dysfunction in Hungary (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top